Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Pediatric Asthma Safety Study
To estimate the effects on HPA axis function for MF/F MDI 50/10 mcg, 100/10 mcg and 200/10 mcg twice daily (BID) in plasma cortisol AUC(0-24 hours) as compared to montelukast 5 mg once daily (QD) (4 m...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of Bicalutamide With or Without Deforolimus in Men With Asymptomatic, Metastatic Castrate-Resistant Prostate Cancer
To determine the efficacy of the combination of ridaforolimus and bicalutamide compared to placebo and bicalutamide by PSA decline within 12 weeks, a surrogate measurement of overall survival efficacy...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A study in adults who have ongoing asthma, using a new product combined with Montelukast
The purpose of this study is to assess the efficacy and safety of MK-1029, compared with placebo, in subjects aged 18 to 75 years with evidence of asthma uncontrolled on montelukast, using measures of...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Assess the effect of switching HIV-1 infected subjects with CNS toxicity (≥ Grade 2) from ATRIPLA™ or its complements to MK-1439A
To evaluate the effect of a switch to MK-1439A compared with continuation of ATRIPLA on the incidence of Grade 2 or worse CNS toxicity (defined as at least one toxicity listed on the CNS toxicity ques...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Pediatric Dose-Ranging of Mometasone Furoate MDI
To demonstrate the dose-related efficacy by evaluating morning lung function at the end of the dosing interval (AM pre-dose percent predicted forced expiratory volume in one second [FEV1]) after 12 we...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Pembrolizumab in advanced renal cell carcinoma
1. To estimate the objective response rate (ORR) per RECIST 1.1 as assessed by BICR in subjects with clear cell RCC. 2. To estimate the ORR per RECIST 1.1 as assessed by BICR in subjects with non-cle...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Immunotherapeutic treatment with Pembrolizumab (antibody) in melanoma patients at high risk of recurrence after complete surgical resection
- To prospectively assess whether post-operative adjuvant therapy with pembrolizumab improves recurrence-free survival, as compared to placebo in high-risk patients with complete resection of Stage II...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Study of MK-1986 (tedizolid phosphate) in children 3 mo to <12 yr with acute bacterial skin and skin structure infections (ABSSSI)
(1) The primary objective is to use descriptive statistics to evaluate the safety of intravenous (IV) and/or oral 6- or 10-day tedizolid phosphate with 10- or 14-day IV and/or oral comparator in subje...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A Phase 3 study in Patients with Type 2 Diabetes Mellitus Studio di fase III su pazienti affetti da diabete mellito di tipo 2
After 24 weeks, to assess the effect of treatment with MK-3102 compared with placebo on A1C. To assess the safety and tolerability of MK-3102. Valutare l’effetto sulla A1C del trattamento con M...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Merck)
MAJ Il y a 5 ans
MK-3475 vs. Docetaxel in Second-Line Non-Small Cell Lung Cancer
1) To compare the overall survival of previously treated subjects with nonsmall cell lung cancer in the strongly positive PDL1 stratum treated with MK3475 compared to docetaxel. 2) To compare progres...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant